Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sondermann

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2004
Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgGKatja Wenig, Lorenz Chatwell, Ulrich von Pawel-Rammingen, et al.
Journal of Chromatography. A|October 11, 2019
FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodiesAnne Freimoser-Grundschober, Petra Rueger, Felix Fingas, et al.
The Journal of Investigative Dermatology|October 21, 2014
Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisitaHiroaki Iwata, Elena Pipi, Nicole Möckel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucoseClaudia Ferrara, Sandra Grau, Christiane Jäger, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Cancer Research|December 5, 2015
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In VivoStefan Lohse, Saskia Meyer, Laura A P M Meulenbroek, et al.
Blood|March 3, 2010
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityEkkehard Mössner, Peter Brünker, Samuel Moser, et al.
Frontiers in Immunology|June 17, 2017
Mechanisms of Autoantibody-Induced PathologyRalf J Ludwig, Karen Vanhoorelbeke, Frank Leypoldt, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2004
Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgGKatja Wenig, Lorenz Chatwell, Ulrich von Pawel-Rammingen, et al.
Journal of Chromatography. A|October 11, 2019
FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodiesAnne Freimoser-Grundschober, Petra Rueger, Felix Fingas, et al.
The Journal of Investigative Dermatology|October 21, 2014
Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisitaHiroaki Iwata, Elena Pipi, Nicole Möckel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucoseClaudia Ferrara, Sandra Grau, Christiane Jäger, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Cancer Research|December 5, 2015
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In VivoStefan Lohse, Saskia Meyer, Laura A P M Meulenbroek, et al.
Blood|March 3, 2010
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityEkkehard Mössner, Peter Brünker, Samuel Moser, et al.
Frontiers in Immunology|June 17, 2017
Mechanisms of Autoantibody-Induced PathologyRalf J Ludwig, Karen Vanhoorelbeke, Frank Leypoldt, et al.
Pageof 2